Verona Pharma Announces New Clinical Trial for Inhaled Lung Therapy RPL554
Verona Pharma, a biopharmaceutical company developing therapeutics for the treatment of respiratory diseases, recently announced the initiation of a clinical trial in the United States for its product RPL554. The drug is currently in development for patients with chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). Announcement of the clinical trial follows the…